Literature DB >> 34405814

Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic.

Murat Törüner1, İsmail Hakkı Kalkan2, Filiz Akyüz3, Ahmet Tezel4, Aykut Ferhat Çelik5.   

Abstract

The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity worldwide and is still a growing problem. Inflammatory bowel disease (IBD) is a chronic inflammatory disease for which a substantial number of patients are treated with immunosuppressive medications, either occasionally or long-term. Despite the accumulating evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive treatment. Moreover, following the emergence of several COVID vaccines, there are concerns regarding vaccine effectiveness and possible side effects in such patients. In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34405814      PMCID: PMC8975298          DOI: 10.5152/tjg.2021.280721

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  45 in total

1.  Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.

Authors:  Colleen Gc McGregor; Alex Adams; Ross Sadler; Carolina V Arancibia-Cárcamo; Rebecca Palmer; Tim Ambrose; Oliver Brain; Alissa Walsh; Paul Klenerman; Simon Pl Travis; Nicholas M Croft; James O Lindsay; Jack Satsangi
Journal:  Gut       Date:  2021-02-12       Impact factor: 23.059

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

3.  Immune response to influenza vaccine in children with inflammatory bowel disease.

Authors:  Ying Lu; Denise L Jacobson; Lori A Ashworth; Richard J Grand; Anthony L Meyer; Monica M McNeal; Matt C Gregas; Sandra K Burchett; Athos Bousvaros
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

4.  Risk factors for opportunistic infections in patients with inflammatory bowel disease.

Authors:  Murat Toruner; Edward V Loftus; W Scott Harmsen; Alan R Zinsmeister; Robert Orenstein; William J Sandborn; Jean-Frederic Colombel; Laurence J Egan
Journal:  Gastroenterology       Date:  2008-01-11       Impact factor: 22.682

5.  ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.

Authors:  T Kucharzik; P Ellul; T Greuter; J F Rahier; B Verstockt; C Abreu; A Albuquerque; M Allocca; M Esteve; F A Farraye; H Gordon; K Karmiris; U Kopylov; J Kirchgesner; E MacMahon; F Magro; C Maaser; L de Ridder; C Taxonera; M Toruner; L Tremblay; M Scharl; N Viget; Y Zabana; S Vavricka
Journal:  J Crohns Colitis       Date:  2021-06-22       Impact factor: 10.020

6.  Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.

Authors:  Erica J Brenner; Ryan C Ungaro; Richard B Gearry; Gilaad G Kaplan; Michele Kissous-Hunt; James D Lewis; Siew C Ng; Jean-Francois Rahier; Walter Reinisch; Frank M Ruemmele; Flavio Steinwurz; Fox E Underwood; Xian Zhang; Jean-Frederic Colombel; Michael D Kappelman
Journal:  Gastroenterology       Date:  2020-05-18       Impact factor: 22.682

7.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

8.  Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn's and Colitis Organization.

Authors:  Ferdinando D'Amico; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Gastroenterology       Date:  2020-04-30       Impact factor: 22.682

9.  Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.

Authors:  Nicholas A Kennedy; James R Goodhand; Nicholas Powell; Tariq Ahmad; Claire Bewshea; Rachel Nice; Desmond Chee; Simeng Lin; Neil Chanchlani; Jeffrey Butterworth; Rachel Cooney; Nicholas M Croft; Ailsa L Hart; Peter M Irving; Klaartje B Kok; Christopher A Lamb; Jimmy K Limdi; Jonathan Macdonald; Dermot Pb McGovern; Shameer J Mehta; Charles D Murray; Kamal V Patel; Richard Cg Pollok; Timothy Raine; Richard K Russell; Christian P Selinger; Philip J Smith; Jack Bowden; Timothy J McDonald; Charlie W Lees; Shaji Sebastian
Journal:  Gut       Date:  2021-03-22       Impact factor: 31.793

10.  The Risk of SARS-CoV-2 in Immunosuppressed IBD Patients.

Authors:  Peter D R Higgins; Siew Ng; Silvio Danese; Krishna Rao
Journal:  Crohns Colitis 360       Date:  2020-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.